pro-drug Heptax/XanCor, CDX-085 [19]
The Numbers Are Sobering: Patients with HH face a 20-fold increased risk of liver cancer, with an absolute risk of 6% among men and 1.5% among women at 10 years of follow-up A comparative study found that patients with HH had a relative risk of 1.8 for developing hepatocellular carcinoma and 1.8 for non-hepatic cancers compared to matched controls with non-iron-related chronic liver disease The incidence of hepatocellular carcinoma in individuals with hereditary hemochromatosis is 200 times greater than in the general population But the cancer risk extends beyond the liver
doi: 10.1016/j.cmet.2016.01.007 101 YunevaMOFanTWAllenTDHigashiRMFerrarisDVTsukamotoTet al
Three main drivers of menstrual dysfunction in PCOS (Wojda, et al., 2025)
Certain gut bacteria produce metabolites that help trigger the release of GLP-1 [1],[2]
Semaglutide and tirzepatide, among other GLP-1 medications, have demonstrated: Significant weight reduction (often over 10% of body weight) Improved glycemic control Cardiovascular benefits (including lower risk of major adverse cardiac events) In pivotal trials like the STEP (semaglutide) and SURMOUNT (tirzepatide) studies, frequent in-person weight monitoring typically every 2 to 4 weeks was an integral component of optimizing these outcomes
